- Home
- NRDY vs AARD Comparison
NRDY vs AARD Comparison
Compare NRDY & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDY
- AARD
- Stock Information
- Founded
- NRDY 2007
- AARD 2017
- Country
- NRDY United States
- AARD United States
- Employees
- NRDY N/A
- AARD N/A
- Industry
- NRDY Computer Software: Prepackaged Software
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- NRDY Technology
- AARD Health Care
- Exchange
- NRDY Nasdaq
- AARD Nasdaq
- Market Cap
- NRDY 191.6M
- AARD 154.9M
- IPO Year
- NRDY N/A
- AARD 2025
- Fundamental
- Price
- NRDY $1.44
- AARD $7.00
- Analyst Decision
- NRDY Hold
- AARD Strong Buy
- Analyst Count
- NRDY 8
- AARD 4
- Target Price
- NRDY $1.90
- AARD $31.50
- AVG Volume (30 Days)
- NRDY 669.6K
- AARD 142.1K
- Earning Date
- NRDY 05-06-2025
- AARD 01-01-0001
- Dividend Yield
- NRDY N/A
- AARD N/A
- EPS Growth
- NRDY N/A
- AARD N/A
- EPS
- NRDY N/A
- AARD N/A
- Revenue
- NRDY $190,231,000.00
- AARD N/A
- Revenue This Year
- NRDY $3.83
- AARD N/A
- Revenue Next Year
- NRDY $9.45
- AARD N/A
- P/E Ratio
- NRDY N/A
- AARD N/A
- Revenue Growth
- NRDY N/A
- AARD N/A
- 52 Week Low
- NRDY $0.73
- AARD $4.88
- 52 Week High
- NRDY $2.84
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- NRDY 47.21
- AARD N/A
- Support Level
- NRDY $1.20
- AARD N/A
- Resistance Level
- NRDY $1.45
- AARD N/A
- Average True Range (ATR)
- NRDY 0.11
- AARD 0.00
- MACD
- NRDY 0.02
- AARD 0.00
- Stochastic Oscillator
- NRDY 76.32
- AARD 0.00
About NRDY Nerdy Inc.
Nerdy Inc is a curated direct-to-consumer platform for live online learning. Its purpose-built proprietary platform leverages technology, including AI, to connect learners of all ages to experts, delivering superior value on both sides of the network. Its comprehensive learning destination provides learning experiences across various subjects and multiple formats including one-on-one instruction, small group classes, large format group classes, and adaptive self-study.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.